We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+1.17%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$47.1B
AUM Growth
-$899M
(-1.9%)
Cap. Flow
-$982M
Cap. Flow
% of AUM
-2.08%
Top 10 Holdings %
Top 10 Hldgs %
35.43%
Holding
967
New
122
Increased
219
Reduced
464
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$250M |
| 2 |
Starbucks
SBUX
|
+$152M |
| 3 |
CERN
Cerner Corp
CERN
|
+$122M |
| 4 |
Colgate-Palmolive
CL
|
+$87.1M |
| 5 |
Procter & Gamble
PG
|
+$77.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$456M |
| 2 |
Cisco
CSCO
|
+$392M |
| 3 |
Analog Devices
ADI
|
+$151M |
| 4 |
United Parcel Service
UPS
|
+$148M |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$89.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.05% |
| 2 | Consumer Discretionary | 15.92% |
| 3 | Financials | 12.69% |
| 4 | Healthcare | 12.47% |
| 5 | Communication Services | 9.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Green Dot
GDOT
$745M
| $24.1M | 0.05% |
375,545
-13,295
| -3% | -$838K |
|
177
UMB Financial
UMBF
$11.1B
| $24M | 0.05% |
332,085
+5,801
| +2% | +$435K |
|
178
Ironwood Pharmaceuticals
IRWD
$714M
| $23.7M | 0.05% |
1,831,301
-55,048
| -3% | -$686K |
|
179
Belden
BDC
$5.19B
| $23.7M | 0.05% |
343,186
-1,504
| -0.4% | -$115K |
|
180
Walt Disney
DIS
$181B
| $23.6M | 0.05% |
235,094
-60,236
| -20% | -$6.4M |
|
181
Armstrong World Industries
AWI
$7.84B
| $23.5M | 0.05% |
417,538
-48,358
| -10% | -$2.93M |
|
|
GWR
182
DELISTED
Genesee & Wyoming Inc.
GWR
| $23.5M | 0.05% |
331,615
-31,791
| -9% | -$2.4M |
|
|
SF
183
Stifel
SF
$12.6B
| $23.4M | 0.05% |
888,597
-25,373
| -3% | -$719K |
|
|
HOME
184
DELISTED
At Home Group Inc.
HOME
| $23.3M | 0.05% |
728,610
+277,418
| +61% | +$8.52M |
|
185
Live Nation Entertainment
LYV
$42.1B
| $23.3M | 0.05% |
552,367
-132,271
| -19% | -$5.87M |
|
186
Granite Construction
GVA
$5.62B
| $22.9M | 0.05% |
409,127
-14,488
| -3% | -$893K |
|
187
MGP Ingredients
MGPI
$375M
| $22.8M | 0.05% |
254,076
+33,243
| +15% | +$2.7M |
|
|
ALE
188
DELISTED
Allete
ALE
| $22.7M | 0.05% |
314,604
-3,200
| -1% | -$226K |
|
189
Labcorp
LH
$25.9B
| $22.7M | 0.05% |
163,175
-24,007
| -13% | -$3.53M |
|
190
Boeing
BA
$185B
| $22.6M | 0.05% |
68,985
-27,090
| -28% | -$9.15M |
|
191
Essent Group
ESNT
$6.33B
| $22.6M | 0.05% |
529,836
-18,958
| -3% | -$860K |
|
192
iRhythm Holdings
IRTC
$4.2B
| $22.4M | 0.05% |
355,997
+20,509
| +6% | +$1.27M |
|
193
Renasant Corp
RNST
$3.91B
| $22.3M | 0.05% |
524,742
-16,421
| -3% | -$706K |
|
194
Pfizer
PFE
$153B
| $22.1M | 0.05% |
657,618
-1,228,058
| -65% | -$42.2M |
|
195
Kinsale Capital Group
KNSL
$8.51B
| $22.1M | 0.05% |
429,616
-13,214
| -3% | -$640K |
|
196
Vistra
VST
$47.4B
| $22M | 0.05% |
1,057,675
-206,446
| -16% | -$3.99M |
|
197
MetLife
MET
$62.1B
| $21.9M | 0.05% |
477,260
-353,563
| -43% | -$17.2M |
|
198
Inogen
INGN
$164M
| $21.9M | 0.05% |
177,947
-5,993
| -3% | -$732K |
|
199
Gray Television
GTN
$552M
| $21.8M | 0.05% |
1,718,976
+90,080
| +6% | +$1.36M |
|
|
TLND
200
DELISTED
Talend S.A. American Depositary Shares
TLND
| $21.8M | 0.05% |
453,262
+305,537
| +207% | +$13M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q1 2018 Portfolio in Review
As of Q1 2018, Loomis, Sayles & Company held 967 positions worth $47.1B, down 1.9% from $48B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Loomis, Sayles & Company's Q1 2018 filing shows 122 new, 219 increased, 464 reduced and 97 closed positions. Its largest new stake was BioMarin Pharmaceuticals: 870,638 shares worth $70.6M. The largest sale was Amazon, an estimated $456M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- Loomis, Sayles & Company's largest Q1 2018 buy was BioMarin Pharmaceuticals: 870,638 shares worth $70.6M.
- Loomis, Sayles & Company added most to Regeneron Pharmaceuticals in Q1 2018, an estimated $250M increase.
- Loomis, Sayles & Company's biggest Q1 2018 reduction was Amazon, cutting an estimated $456M.
- Loomis, Sayles & Company fully exited Analog Devices in Q1 2018, selling an estimated $151M.
- Loomis, Sayles & Company's ten largest holdings make up 35% of its $47.1B portfolio in Q1 2018.
- Loomis, Sayles & Company opened 122 new positions and closed 97 in Q1 2018.
- Loomis, Sayles & Company's portfolio value fell 1.9% quarter-over-quarter to $47.1B.
Based on Loomis, Sayles & Company's 13F filing for Q1 2018, filed 11 May 2018.